J. Thaler

1.3k total citations
41 papers, 874 citations indexed

About

J. Thaler is a scholar working on Oncology, Genetics and Pulmonary and Respiratory Medicine. According to data from OpenAlex, J. Thaler has authored 41 papers receiving a total of 874 indexed citations (citations by other indexed papers that have themselves been cited), including 23 papers in Oncology, 15 papers in Genetics and 10 papers in Pulmonary and Respiratory Medicine. Recurrent topics in J. Thaler's work include Chronic Lymphocytic Leukemia Research (15 papers), Colorectal Cancer Treatments and Studies (14 papers) and Lung Cancer Treatments and Mutations (8 papers). J. Thaler is often cited by papers focused on Chronic Lymphocytic Leukemia Research (15 papers), Colorectal Cancer Treatments and Studies (14 papers) and Lung Cancer Treatments and Mutations (8 papers). J. Thaler collaborates with scholars based in Austria, Germany and France. J. Thaler's co-authors include G. Solbu, Stefan Suciu, M. Peetermans, Franco Mandelli, Roel Willemze, Wolfgang Hilbe, R Zittoun, P Stryckmans, Anthony D. Ho and Pierre Stryckmans and has published in prestigious journals such as Journal of Clinical Oncology, Blood and JNCI Journal of the National Cancer Institute.

In The Last Decade

J. Thaler

40 papers receiving 850 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
J. Thaler Austria 14 468 266 250 248 142 41 874
Alain Sadoun France 12 249 0.5× 158 0.6× 209 0.8× 432 1.7× 173 1.2× 28 820
SN Wolff United States 10 397 0.8× 277 1.0× 229 0.9× 421 1.7× 65 0.5× 13 822
C Bayle France 14 264 0.6× 333 1.3× 189 0.8× 185 0.7× 104 0.7× 39 767
Vincenzo Pavone Italy 16 460 1.0× 617 2.3× 263 1.1× 389 1.6× 146 1.0× 61 1.1k
M Bertini Italy 16 379 0.8× 586 2.2× 225 0.9× 145 0.6× 135 1.0× 44 901
Jens Ersbøll Denmark 15 381 0.8× 449 1.7× 282 1.1× 371 1.5× 188 1.3× 29 1.1k
Nicole Straetmans Belgium 17 572 1.2× 546 2.1× 333 1.3× 272 1.1× 75 0.5× 44 1.1k
Paule‐Marie Carli France 13 274 0.6× 223 0.8× 225 0.9× 376 1.5× 91 0.6× 29 822
Lyndah Dreiling United States 16 464 1.0× 303 1.1× 408 1.6× 217 0.9× 150 1.1× 50 932
J. M. Vose United States 15 596 1.3× 801 3.0× 289 1.2× 243 1.0× 115 0.8× 34 1.2k

Countries citing papers authored by J. Thaler

Since Specialization
Citations

This map shows the geographic impact of J. Thaler's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by J. Thaler with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites J. Thaler more than expected).

Fields of papers citing papers by J. Thaler

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by J. Thaler. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by J. Thaler. The network helps show where J. Thaler may publish in the future.

Co-authorship network of co-authors of J. Thaler

This figure shows the co-authorship network connecting the top 25 collaborators of J. Thaler. A scholar is included among the top collaborators of J. Thaler based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with J. Thaler. J. Thaler is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Taı̈eb, Julien, Karine Le Malicot, Josep Tabernero, et al.. (2016). Adjuvant FOLFOX+ cetuximab vs FOLFOX in full RAS and BRAF wild type stage III colon cancer patients: Results from the PETACC8 trial. Annals of Oncology. 27. vi152–vi152. 2 indexed citations
2.
Steurer, Michael, Lydia Scarfò, Marco Montillo, et al.. (2014). INTERIM RESULTS FROM A PHASE IIA STUDY OF THE ANTI-CXCL12 SPIEGELMER OLAPTESED PEGOL (NOX-A12) IN COMBINATION WITH BENDAMUSTINE/RITUXIMAB IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA. Haematologica. 99. 59–59. 2 indexed citations
3.
Taı̈eb, Julien, Josep Tabernero, Enrico Mini, et al.. (2014). Oxaliplatin, fluorouracil, and leucovorin with or without cetuximab in patients with resected stage III colon cancer (PETACC-8): an open-label, randomised phase 3 trial. The Lancet Oncology. 15(8). 862–873. 188 indexed citations
4.
Gruenberger, Thomas, Friedrich Laengle, J. Thaler, et al.. (2010). Pre- and postoperative chemotherapy including bevacizumab in potentially curable metastatic colorectal cancer: A multicenter, single-arm phase II trial—Results of ASSO LM1.. Journal of Clinical Oncology. 28(15_suppl). e14032–e14032. 1 indexed citations
5.
Karthaus, Meinolf, Ralf‐Dieter Hofheinz, Laurent Mineur, et al.. (2009). Epidermal growth factor receptor (EGFR) inhibitor–related skin toxicity: Review of interim data from a phase II study (20060314) of panitumumab (pmab) with FOLFIRI in the first-line treatment of metastatic colorectal cancer (mCRC). Journal of Clinical Oncology. 27(15_suppl). e20634–e20634. 6 indexed citations
6.
Eisterer, Wolfgang, A. de Vries, Richard Greil, et al.. (2009). Neoadjuvant chemoradiation therapy with capecitabine (X) plus cetuximab (C), and external beam radiotherapy (RT) in locally advanced rectal cancer (LARC): ABCSG trial R03. Journal of Clinical Oncology. 27(15_suppl). 4109–4109. 10 indexed citations
7.
8.
Kühr, Thomas, Wolfgang Eisterer, K. Gattringer, et al.. (2006). Oxaliplatin and irinotecan chemotherapy in advanced gastric cancer. Final results of a multicenter phase II trial. Journal of Clinical Oncology. 24(18_suppl). 4070–4070. 2 indexed citations
9.
Hilbe, Wolfgang, Walter Nußbaumer, Hugo Bonatti, et al.. (2000). Unusual adverse events following peripheral blood stem cell (PBSC) mobilisation using granulocyte colony stimulating factor (G-CSF) in healthy donors. Bone Marrow Transplantation. 26(7). 811–813. 13 indexed citations
10.
Hilbe, Wolfgang, Thomas Berger, G Konwalinka, & J. Thaler. (1999). Cladribine Treatment of a Patient with Hairy Cell Leukemia and Concomitant Multiple Sclerosis. Acta Haematologica. 102(2). 99–100. 2 indexed citations
11.
12.
Schirmer, Michael, Erich Mur, Karl Pfeiffer, J. Thaler, & G Konwalinka. (1997). The Safety Profile of Low-dose Cladribine in Refractory Rheumatoid Arthritis. Scandinavian Journal of Rheumatology. 26(5). 376–379. 31 indexed citations
13.
Schirmer, Michael, et al.. (1997). T Cells and Natural Killer Cells after Treatment of Hairy Cell Leukaemia with 2-Chlorodeoxyadenosine. Acta Haematologica. 97(3). 180–183. 13 indexed citations
14.
15.
Hilbe, Wolfgang, et al.. (1996). An aggressive subtype of B‐CLL is characterized by strong CD44 expression and lack of CD11c. British Journal of Haematology. 93(3). 661–669. 29 indexed citations
16.
Zittoun, R, Stefan Suciu, G. Solbu, et al.. (1995). Comparison of quality of life (QOL) of patients with acute myelogenous leukemias (AML) in long-term first complete remission (CR) after bone marrow transplantation (BMT) - Allogeneic or autologous - Or intensive chemotherapy consolidation (ICC): EORTC-GIMEMA AML 8A study. Blood. 86(10). 1718–1718. 1 indexed citations
17.
Döhner, H., Anthony D. Ho, J. Thaler, et al.. (1993). Pentostatin in Prolymphocytic Leukemia: Phase II Trial of the European Organization for Research and Treatment of Cancer Leukemia Cooperative Study Group. JNCI Journal of the National Cancer Institute. 85(8). 658–662. 51 indexed citations
18.
Thaler, J., Kurt Grünewald, Anthony D. Ho, et al.. (1993). Long‐term follow‐up of patients with hairy cell leukaemia treated with pentostatin: lymphocyte subpopulations and residual bone marrow infiltration. British Journal of Haematology. 84(1). 75–82. 25 indexed citations
19.
Ho, Anthony D., J. Thaler, F. Lauria, et al.. (1990). Pentostatin (2′-deoxycoformycin) for the treatment of lymphoid neoplasms. Cancer Treatment Reviews. 17(2-3). 213–215. 14 indexed citations
20.
Nachbaur, David, H. Denz, Günther Gastl, et al.. (1989). Combination effects of human recombinant interferon (alpha-2-arg, gamma) and cytotoxic agents on colony formation of human melanoma and hypernephroma cell lines. Cancer Letters. 44(1). 49–53. 7 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Alain Sadoun Breakdown of academic impact, for papers by SN Wolff Breakdown of academic impact, for papers by C Bayle Breakdown of academic impact, for papers by Vincenzo Pavone Breakdown of academic impact, for papers by M Bertini Breakdown of academic impact, for papers by Jens Ersbøll Breakdown of academic impact, for papers by Nicole Straetmans Breakdown of academic impact, for papers by Paule‐Marie Carli Breakdown of academic impact, for papers by Lyndah Dreiling Breakdown of academic impact, for papers by J. M. Vose
Rankless by CCL
2026